Arix Bioscience
plc
Correction:
Results of Annual General Meeting
With correction to Table of
Resolutions – Numbers 02 and 03.
LONDON, 03 June 2019: Arix Bioscience plc (“Arix”,
LSE: ARIX) a global venture capital company focused on investing
and building breakthrough biotech companies, announces that its
Annual General Meeting (the "Meeting") was held on Monday,
3 June 2019 at 10.30am (BST). At the Meeting, the ordinary and
special resolutions set out in the Notice of the Annual General
Meeting dated 2 May 2019 (the "Notice
of AGM"), were proposed and voted on by way of a poll.
Full details of the poll results are set out below and will also
be available on the Company's website www.arixbioscience.com.
No |
RESOLUTION |
VOTES FOR |
% |
VOTES
AGAINST |
% |
TOTAL
VOTES |
% of ISC
VOTED |
VOTES
WITHHELD |
01 |
To receive the
Directors' report and the accounts for the Company for the year
ended 31 December 2018 |
79,740,015 |
100.00 |
0 |
0.00 |
79,740,015 |
58.86% |
3,894 |
02 |
To approve the
Directors' Remuneration Policy |
40,079,954 |
50.26 |
39,658,365 |
49.74 |
79,738,319 |
58.86% |
5,590 |
03 |
To approve the
Directors' Remuneration Report for the year ended 31 December
2018 |
23,179,050 |
32.41 |
48,338,181 |
67.59 |
71,517,231 |
52.79% |
8,226,678 |
04 |
To re-elect Jonathan
Peacock as a Director |
75,716,711 |
94.95 |
4,025,628 |
5.05 |
79,742,339 |
58.86% |
1,570 |
05 |
To re-elect Dr Franz
Humer as a Director |
74,175,937 |
93.02 |
5,566,402 |
6.98 |
79,742,339 |
58.86% |
1,570 |
06 |
To re-elect Professor
Trevor Jones as a Director |
77,691,164 |
97.43 |
2,050,547 |
2.57 |
79,741,711 |
58.86% |
2,198 |
07 |
To re-elect Giles Kerr
as a Director |
79,739,711 |
100.00 |
2,628 |
0.00 |
79,742,339 |
58.86% |
1,570 |
08 |
To re-elect Dr Joseph
Anderson as a Director |
79,741,711 |
100.00 |
628 |
0.00 |
79,742,339 |
58.86% |
1,570 |
09 |
To re-elect James
Rawlingson as a Director |
79,741,711 |
100.00 |
628 |
0.00 |
79,742,339 |
58.86% |
1,570 |
10 |
To elect Art Pappas as
a Director |
76,266,164 |
95.64 |
3,476,175 |
4.36 |
79,742,339 |
58.86% |
1,570 |
11 |
To elect Mark Breuer
as a Director |
79,741,711 |
100.00 |
0 |
0.00 |
79,741,711 |
58.86% |
2,198 |
12 |
To re-appoint PwC LLP
as auditors of the Company |
72,224,733 |
90.57 |
7,524,156 |
9.43 |
79,748,889 |
58.87% |
4,020 |
13 |
To authorise the Audit
& Risk Committee of the Company to fix the remuneration of the
auditors |
78,313,875 |
98.21 |
1,426,485 |
1.79 |
79,740,360 |
58.86% |
3,549 |
14 |
To authorise the
Directors to allot shares |
73,634,398 |
92.34 |
6,105,491 |
7.66 |
79,739,889 |
58.86% |
4,020 |
15 |
To authorise the
Directors to disapply statutory pre- emption rights in respect of
5% of the Company's issued
share capital* |
70,676,320 |
88.63 |
9,063,088 |
11.37 |
79,739,408 |
58.86% |
4,501 |
16 |
To authorise the
Directors to disapply statutory pre- emption rights in respect of
an additional 5% of the
Company's issued share capital* |
71,033,320 |
89.08 |
8,706,088 |
10.92 |
79,739,408 |
58.86% |
4,501 |
17 |
To authorise the
Company to buy back shares* |
79,736,396 |
99.99 |
5,063 |
0.01 |
79,741,459 |
58.86% |
2,450 |
18 |
To authorise the
Directors to call a general meeting other than an annual general
meeting on not less than 14 clear days' notice* |
79,739,242 |
100.00 |
2,250 |
0.00 |
79,741,492 |
58.86% |
2,417 |
* Special resolution
In accordance with Listing Rule 9.6.2, copies of resolutions
passed at the Meeting concerning items other than ordinary business
will shortly be available for inspection on the National Storage
Mechanism, which can be accessed at www.hemscott.com/nsm.do
The Board is pleased that all resolutions at the meeting were
passed other than the resolution to approve last year’s Directors’
Remuneration Report, Resolution 3. Over the next six months we
shall engage with those shareholders we can identify who did not
support this resolution to fully understand their concerns.
Engagement will also take place with the small number of
shareholders who did not support the resolution to approve the new
Directors’ Remuneration Policy, which was passed but with a
significant minority of votes against.
Since being set up in 2016, the Arix portfolio has grown and
developed with 17 investments to date and four IPOs of portfolio
companies in the past year. Multiple clinical milestones are
expected over the next 12 months and the Company looks forward to
reporting on continued progress throughout the year.
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
T: +44 (0) 203 922 0891
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com